Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"Presenting the TRIPP-FFX results at ESMO GI 2026 represents an important milestone for OncoSil Medical and provides the opportunity to share our data with one of the world's leading audiences of gastrointestinal oncology specialists. Importantly, the presentation included new, Per Protocol analysis, which demonstrated a median overall survival of 21.3 months together with encouraging efficacy outcomes across multiple clinically meaningful secondary endpoints. This new analysis further strengthens the clinical evidence supporting the use of the OncoSil™ device alongside FOLFIRINOX in patients with unresectable LAPC.

 The continued demonstration of a manageable safety profile with no new safety signals, together with the encouraging efficacy outcomes presented at ESMO GI, further strengthens our confidence as we progress our planned Change Notification submission to expand the OncoSil™ device label to include FOLFIRINOX, subject to regulatory approval."